FBL8 Activators
FBL8 activators encompass a diverse array of compounds that facilitate the modulation of this protein's role in cellular signaling and protein ubiquitination pathways. Forskolin, for instance, augments the functional activity of FBL8 by activating adenylyl cyclase, which in turn increases intracellular cAMP levels - a critical component of the cAMP-dependent signaling pathways in which FBL8 is implicated. The resultant rise in cAMP enhances FBL8's interaction with target proteins, thereby promoting its functional role. Similarly, Phorbol 12-myristate 13-acetate (PMA) activates protein kinase C (PKC), which phosphorylates substrates that interact with FBL8, thereby enhancing its involvement in protein ubiquitination within the cell. Arachidonic Acid serves as a precursor to eicosanoids that initiate signaling cascades culminating in the activation of kinases that upregulate FBL8, enhancing its role in the degradation of target proteins. Furthermore, Sphingosine-1-phosphate (S1P) activates G-protein-coupled receptors to engage signaling pathways involving FBL8, potentially increasing its efficiency in mediating protein ubiquitination as part of cellular signal transduction.
Additionally, FBL8's activity is also bolstered by molecules like Epigallocatechin gallate (EGCG), which inhibits kinases that otherwise compete with FBL8's ubiquitination pathways, thus supporting its function. Lithium Chloride, by influencing the Wnt signaling pathway, indirectly enhances FBL8's role in the ubiquitination and degradation of proteins. SB203580 and U0126, inhibitors of p38 MAPK and MEK respectively, modify the phosphorylation status of FBL8's potential substrates, facilitating their ubiquitination by FBL8. PI3K inhibitors such as LY294002 and Wortmannin diminish the phosphorylation of downstream targets, allowing FBL8 to more effectively ubiquitinate these proteins. Rapamycin, by inhibiting mTOR, leads to the reduction in phosphorylation of proteins that may serve as substrates for FBL8, thus supporting FBL8's activity in protein ubiquitination.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin activates adenylyl cyclase, increasing intracellular cAMP levels. FBL8 is implicated in cAMP-dependent signal pathways, and the rise in cAMP can enhance FBL8 activity by promoting its interaction with target proteins involved in this signaling cascade. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA activates protein kinase C (PKC), which then can phosphorylate substrates that interact with FBL8. This phosphorylation can enhance FBL8’s role in protein ubiquitination processes within the cell. | ||||||
Arachidonic Acid (20:4, n-6) | 506-32-1 | sc-200770 sc-200770A sc-200770B | 100 mg 1 g 25 g | $92.00 $240.00 $4328.00 | 9 | |
As a precursor for eicosanoids, Arachidonic Acid can initiate signaling pathways that involve protein kinase activation. FBL8, associated with protein degradation processes, can be upregulated as a result of these signals, enhancing its functional activity. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $165.00 $322.00 $570.00 $907.00 $1727.00 | 7 | |
S1P engages with G-protein-coupled receptors to activate signaling pathways that involve FBL8. This lipid signaling molecule can enhance the function of FBL8 in mediating the ubiquitination of proteins as part of signal transduction. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
EGCG inhibits several kinases, potentially leading to altered ubiquitination pathways where FBL8 is active. By inhibiting competitive signaling, EGCG enhances the functional activity of FBL8 in its specific pathway. | ||||||
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
Lithium influences the Wnt signaling pathway, which can impact protein degradation systems involving FBL8. By altering this pathway, Lithium can enhance FBL8's role in the ubiquitination and degradation of proteins. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor, this reduces the competitive phosphorylation of proteins that may be substrates for FBL8, enhancing FBL8's activity in protein ubiquitination. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor, reducing the phosphorylation of downstream targets. Reduced activity in this pathway can enhance FBL8's role in the ubiquitination of these targets. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor, similarly to LY294002, it can lead to reduced phosphorylation of proteins within the PI3K pathway and enhance the functional activity of FBL8 in targeting these proteins for ubiquitination. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, which can lead to a reduction in the phosphorylation of proteins that are potential substrates for FBL8, thereby enhancing the role of FBL8 in their ubiquitination. | ||||||